Serum IL-31 levels are also increased by cilofexor in NASH, PSC, and PBC patients who are treated with this FXR agonist, suggesting a potential explanation for itching caused by FXR ligands [94]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.